Skip to main content

Nonlinearity detection: Advantages of nonlinear mixed-effects modeling

AAPS PharmSci volume 2, pages 114–123 (2000)Cite this article

Abstract

The purpose of this study was to address the question of whether the use of nonlinear mixed-effect models has an impact on the detection and characterization of nonlinear processes (pharmacokinetic and pharmacodynamic) in rich data obtained from a few subjects. Simulations were used to assess the difference between applying population analysis, ie, nonlinear mixed-effects models as implemented in NONMEM, and the standard 2-stage (STS) method as the data analysis method for detection and characterization of nonlinearities. Three situations were considered, 2 pharmacokinetic and 1 pharmacodynamic. Both the first-order (FO) and FO conditional estimation (FOCE) algorithms were used for the population analyses. Within each situation, rich data were simulated for 8 subjects at multiple dose levels. The true nonlinear model and a simpler linear model were fit to each data set using each of the STS, FO, and FOCE methods. Criteria were prespecified to determine when each data analysis method detected the true nonlinear model. For all 3 simulated situations, the application of population analysis with the FOCE algorithm enabled the detection and characterization of the true nonlinear models in at least a 4-fold lower dose level than the STS approach. For both of the pharmacokinetic settings, population analysis with the FO algorithm performed much more poorly than the STS approach. The superior detection and characterization of nonlinearities provided by population analysis with the FOCE algorithm should allow drug developers to better predict and define how a drug should be used in clinical practice in such situations.

This is a preview of subscription content, access via your institution.

Access options

Buy single article

Instant access to the full article PDF.

43,34 €

Price includes VAT (Finland)
Tax calculation will be finalised during checkout.

References

  1. Ludden TM. Nonlinear pharmacokinetics. Clinical Implications. Clin Pharmacokinet. 1991;20:429–446

    CAS  PubMed  Article  Google Scholar 

  2. Dutta S, Matsumoto Y, Ebling WF. Is it possible to estimate the parameters of the sigmoid Emax model with truncated data typical of clinical studies? J Pharm Sci. 1996;85232–239.

    CAS  PubMed  Article  Google Scholar 

  3. Spigset O. The selective serotonin reuptake inhibitor fluvoxamine. Ume niversity medical dissertations, 1997.

  4. Blackledge GRP. High-dose bicalutamide monotherapy for the treatment of prostrate cancer. Urology 1996;47(suppl 1A):44–47

    CAS  PubMed  Article  Google Scholar 

  5. Sedman AJ, Wagner JG. Importance of the use of the appropriate pharmacokinetic model to analyse in vivo enzyme constants J Pharmacokin Biopharm. 1974;2:161–173

    CAS  Article  Google Scholar 

  6. Sheiner LB, Rosenberg B, Marathe VV. Estimation of population characteristics of pharmacokinetic parameters from routine clinical data J Pharmacokin Biopharm. 1977;5:445–479.

    CAS  Article  Google Scholar 

  7. Sheiner LB, Beal SL. Evaluation of methods for estimating population pharmacokinetic parameters. ii. Biexponential model and experimental pharmacokinetic data. J Pharmacokin. Biopharm. 1981;9:635–651.

    CAS  Article  Google Scholar 

  8. Graves DA, Chang I. Application of NONMEM to routine bioavailability data. J Pharmacokin Biopharm. 1990;18:145–160.

    CAS  Article  Google Scholar 

  9. Aarons O, Mandema JW, Danhof M A population analysis of the pharmacokinetics and pharmacodynamics of midazolam in the rat. J Pharmacokin Biopharm. 1991;19:485–496.

    CAS  Article  Google Scholar 

  10. Beal SL, Sheiner LB. NONMEM Users Guides. NONMEM Project Group, University of California at San Francisco, 1992.

  11. Schoemaker RC, Cohen AF. Estimating impossible curves using NONMEM. B J Clin Pharmacol. 1996;42:283–290.

    CAS  Article  Google Scholar 

  12. Hashimoto Y, Mori S, Hama N, Nakao K, Imura H, Yamaguchi M, Yasuhara M, Hori R. Nonlinear mixed effect modelling of the pharmacodynamics of natriuretic peptides in rats. J Pharmacokin Biopharm. 1993;21:281–297.

    CAS  Article  Google Scholar 

  13. Hashimoto Y, Odani A, Tanigawara Y, Yasuhara M, Okuno T, and Hori R. Population analysis of the dose-dependent pharmacokinetics of zonisamide in epileptic patients. Biol Pharm Bull. 1994;17:323–326.

    CAS  PubMed  Article  Google Scholar 

  14. Hashimoto Y, Ozaki J, Koue T, Odani A, Yasuhara M, Hori R. Simulation for the analysis of distorted pharmacodynamic data. Pharm Res. 1994;11:545–548.

    CAS  PubMed  Article  Google Scholar 

  15. Beal SL, Sheiner LB. NONMEM Users Guide—Part VII. Conditional estimation methods. University of California at San Francisco, November 1992.

  16. Rodman JH, Silverstein K. Comparison the two stage (TS) and first order (FO) methods for estimation of population parameters in an intensive pharmacokinetic study. Clin Pharmacol Ther. 1990;47:151.

    Google Scholar 

  17. Godfrey KR, Fitch WR. The deterministic identifiability of nonlinear pharmacokinetic models. J. Pharmacokin Biopharm. 1984;12:177–191.

    CAS  Article  Google Scholar 

  18. Godfrey KR, Fitch WR. On the identification of Michaelis-Menton elimination parameters from a single dose-response curve. J Pharmacokin Biopharm. 1984;12:193–221.

    CAS  Article  Google Scholar 

  19. Godfrey KR, Chapman MJ, Vajda S. Identifiability and indistinguishability of nonlinear pharmacokinetic models. J Pharmacokin Biopharm. 1994;22:229–251.

    CAS  Article  Google Scholar 

  20. Hashimoto Y, Koue T, Otsuki Y, Yasuhara M, Hori R, Inui K. Simulation for population analysis of Michaelis-Menton kinetics. J Pharmacokin Biopharm. 1995;23:205–216.

    CAS  Article  Google Scholar 

Download references

Author information

Affiliations

  1. Department of Pharmacy, Division of Biopharmaceutics and Pharmacokinetics, Uppsala University, Box 580, S-751 23, Uppsala, Sweden

    E. Niclas Jonsson & Mats O. Karlsson

  2. Medical Products Agency, Box 26, S-751 03, Uppsala, Sweden

    Janet R. Wade

Authors
  1. E. Niclas Jonsson
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Mats O. Karlsson
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Janet R. Wade
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to E. Niclas Jonsson.

Additional information

Published: September 25, 2000

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Jonsson, E.N., Karlsson, M.O. & Wade, J.R. Nonlinearity detection: Advantages of nonlinear mixed-effects modeling. AAPS PharmSci 2, 114–123 (2000). https://doi.org/10.1208/ps020332

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1208/ps020332

Key words

  • Population Analysis
  • Nonlinear Mixed-Effects Modeling
  • Nonlinear Pharmacokinetics and Pharmacodynamics
  • Study Design